Semaglutide and Heart Health: The Trial That Changed What These Drugs Are For

Published July 18, 2026

Most Patients Come for the Scale. The Data Went Somewhere Else.

Ask why people start semaglutide and the answer is nearly always weight. Fair enough — 14.9% mean loss in STEP 1 is why the drug is famous.

But the most consequential GLP-1 trial of the decade wasn't a weight trial at all. SELECT set out to answer a harder question: in people who already had cardiovascular disease, does semaglutide prevent the events that kill them?

What SELECT Did

17,604 adults across 41 countries. Entry criteria: age 45+, BMI 27+, established cardiovascular disease — a prior heart attack, stroke, or peripheral arterial disease — and no diabetes. Randomized to weekly semaglutide 2.4mg or placebo; followed a median of 33–40 months for major adverse cardiovascular events.

Result: a 20% relative reduction in heart attack, stroke, and cardiovascular death. Statistically robust, clinically meaningful, and — notably — the benefit appeared early, before maximal weight loss accrued, suggesting mechanisms beyond weight alone: effects on inflammation, blood pressure, and lipids are all under investigation.

The FDA found it persuasive enough to expand Wegovy's label in March 2024 to cardiovascular risk reduction — the first anti-obesity medication with that indication.

Who This Actually Changes Things For

Consider the overlap: BMI 27+, plus a history of heart attack, stroke, or PAD. That describes millions of US adults — many of whom have dismissed GLP-1s as "vanity drugs" or been dismissed by coverage policies treating them that way. For this population the calculus is different: treatment carries a documented reduction in the events they're most at risk of.

It also reframes the affordability problem this article sits beside. When a medication reduces heart attacks, the cost of not affording it isn't measured in pounds. The affordability data — half of users straining to pay, income predicting who stays on therapy — reads differently once the stakes include cardiovascular events.

The Caveat That Matters Here

SELECT studied Wegovy — FDA-approved semaglutide, at 2.4mg, in a monitored trial population. Compounded semaglutide contains the same active ingredient when properly sourced, but no compounded product has cardiovascular outcomes data, and none is FDA-approved. Patients with cardiac histories deserve that distinction stated plainly: the branded pathway carries the evidence; the compounded pathway carries the price. A licensed provider — which every Ozari patient sees before any prescription — is where that individual tradeoff belongs, alongside your full cardiac history.

For pricing across both pathways: branded now runs $245/month via federal pricing, compounded from $86/month — the full map is in our 2026 options guide.

Frequently Asked Questions

Does semaglutide reduce heart attack risk?

In SELECT, semaglutide 2.4mg reduced major adverse cardiovascular events by 20% versus placebo in adults with overweight/obesity and established cardiovascular disease, without diabetes.

Who qualifies under the cardiovascular indication?

The FDA's expanded Wegovy indication covers adults with obesity or overweight and established cardiovascular disease. Individual eligibility is a provider determination.

Does compounded semaglutide have the same heart benefits?

Unknown — outcomes trials studied FDA-approved semaglutide only. Compounded products are not FDA-approved and lack outcomes data; patients with cardiac histories should weigh this with a licensed provider.

Did the benefit come only from weight loss?

The event curves separated earlier than weight-loss timing alone would predict, suggesting additional mechanisms — an active research question.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved. Clinical trial results describe FDA-approved formulations in study populations and are not guarantees of individual outcomes. Always consult a licensed healthcare provider before starting, changing, or stopping any prescription medication.

Sources

treatment